Drugs / I-123 Ioflupane
I-123 Ioflupane
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01453127 | Oct 2011 → Dec 2026 expected | REM sleep behavior disorder, cognitive impairment with or without cerebellar ataxia, dementia, parkinsonian disorder | Mayo Clinic | Enrolling by invitation | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | I-123 Ioflupane | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01453127 ↗ |
| Known as | DaTscan | “DaTscan [Ioflupane (123I)] imaging” NCT01453127 ↗ |
| Known as | Ioflupane (123I) | “DaTscan [Ioflupane (123I)] imaging” NCT01453127 ↗ |
| Modality | Diagnostic / imaging agent | “DaTscan is the one of the first radiopharmaceutical agents available to detect DaT distribution within the brain.” NCT01453127 ↗ |
| Route | Intravenous | “DaTscan is administered by intravenous cannula.” NCT01453127 ↗ |